Search

Displaying results 1531 - 1540 of 10000 in total
  1. Drug

    Influenza B virus B/Phuket/3073/2013 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10793
    ApprovedInvestigational

    A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus

    Mixtures: INFLUVAC S TETRA, INFLUVAC S TETRACategories: Inactivated Influenza B Virus Vaccine
  2. Drug

    Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigen

    go.drugbank.com/drugs/DB15514
    ApprovedWithdrawn

    A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. … Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus

    Synonyms: Influenza A virus A/Kansas/14/2017 (H3N2) live (attenuated) antigenMixtures: INFLUVAC S, INFLUVAC S
  3. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.

  4. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193671] One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38. … As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.

    Categories: Trop-2-Directed Monoclonal AntibodiesProducts: TRODELVY®, TRODELVY 200 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADET
  5. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". … Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy.

    Synonyms: 5-azaorotic acidMixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20
  6. Drug

    Elgemtumab

    go.drugbank.com/drugs/DB15430
    Investigational

    Elgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

  7. Drug

    Cyclobenzaprine

    go.drugbank.com/drugs/DB00924
    ApprovedInvestigational

    [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond. … [A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.

    Mixtures: NOpiod-TC, NOpioid-TCCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 Substrates
  8. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014. … [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesProducts: MEKINIST®2 MG TABLETAS RECUBIERTAS, MEKINIST 2 MG FILM KAPLI TABLET ,7 TABLET
  9. Pathway

    Sarcosinemia

    smpdb.ca/view/SMP0125579
    Disease

    Sarcosine can also be formed in a reversible reaction from S-adenosylmethionine and glycine, using glycine N-methyltransferase as the enzyme, and forming S-adenosylhomocysteine as another product. … This, along with homocysteine, react using betaine-homocysteine S-methyltransferase to form L-methionine, as well as dimethylglycine.

    Drugs: Pyridoxal phosphate · Tetrahydrofolic acid · Ademetionine · Pyruvic acid · Arginine · Adenosine phosphate +26 more
    Enzymes: Betaine--homocysteine S-methyltransferase 1
  10. Drug

    Roflumilast

    go.drugbank.com/drugs/DB01656
    ApprovedInvestigational

    [L37564,A251385] The oral formulation of roflumilast is indicated to manage chronic obstructive pulmonary disease. … [L46541] On December 15, 2023, the FDA approved a new topical foam formulation of roflumilast for the treatment of seborrheic dermatitis in patients aged 9 years and older.[L49281]

    Categories: Agents to Treat Airway Disease, Cytochrome P-450 SubstratesProducts: DAXAS®